Bright idea in dentist's office leads to innovative smoking cessation project
Results from this study recently published online in Addiction found primary care physicians providing smokers with a free, two week starter kit of nicotine replacement therapy (NRT) increased quit attempts While sitting in the dentist's office, Hollings Cancer Center researcher Matthew Carpenter, Ph.D., of the Medical University of South Carolina, had a bright idea. As he received his goody bag with dental hygiene products, he wondered why not conduct a study and have primary care providers do the same thing for their patients who use tobacco. The bags would contain educational material, free lozenges and tobacco cessati...
Source: Dental Technology Blog - February 12, 2020 Category: Dentistry Source Type: news

FDA Lifts Clinical Hold for MultiTAA T-Cell Therapy Trial in Acute Myeloid Leukemia
The planned trial will investigate the safety and efficacy of the novel multi-tumor associated antigen T-cell therapy in patients with post-transplant acute myeloid leukemia. (Source: CancerNetwork)
Source: CancerNetwork - February 12, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Roche announces CHMP recommendation for EU approval of Venclyxto plus Gazyvaro for people with untreated chronic lymphocytic leukaemia
Basel, 31 January 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Venclyxto® (venetoclax) in combination with Gazyvaro® (obinutuzumab) for the treatment of adults with previously untreated chronic lymphocytic leukaemia (CLL).“Despite advances in treating chronic lymphocytic leukaemia, many patients cannot tolerate the side effects of chemotherapy-containing regimens,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product ...
Source: Roche Investor Update - January 31, 2020 Category: Pharmaceuticals Source Type: news

Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia
The initiating mutations that contribute to cancer development are sometimes present in premalignant cells. Whether therapies targeting these mutations can eradicate premalignant cells is unclear. Acute myeloid leukemia (AML) is an attractive system for investigating the effect of preventative treatment because this disease is often preceded by a premalignant state (clonal hematopoiesis or myelodysplastic syndrome). In Npm1c/Dnmt3a mutant knock-in mice, a model of AML development, leukemia is preceded by a period of extended myeloid progenitor cell proliferation and self-renewal. We found that this self-renewal can be reve...
Source: ScienceNOW - January 30, 2020 Category: Science Authors: Uckelmann, H. J., Kim, S. M., Wong, E. M., Hatton, C., Giovinazzo, H., Gadrey, J. Y., Krivtsov, A. V., Rücker, F. G., Döhner, K., McGeehan, G. M., Levine, R. L., Bullinger, L., Vassiliou, G. S., Armstrong, S. A. Tags: Medicine, Diseases reports Source Type: news

Cheap drug may alleviate treatment-resistance in leukemia
(Karolinska Institutet) A common and inexpensive drug may be used to counteract treatment resistance in patients with acute myeloid leukemia (AML), one of the most common forms of blood cancer. This is the conclusion of a study in mice and human blood cells performed at Karolinska Institutet and SciLifeLab and published in the medical journal EMBO Molecular Medicine. The researchers will now launch a clinical study to test the new combination treatment in patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 17, 2020 Category: International Medicine & Public Health Source Type: news

A solid vaccine for liquid tumors
(Wyss Institute for Biologically Inspired Engineering at Harvard) Acute myeloid leukemia (AML) is a deadly blood cancer that kills most of its victims within five years. Chemotherapy has been the standard treatment for over 40 years, and while it often causes the cancer to go into remission, nearly half of patients experience disease relapse. Scientists at the Wyss Institute and Harvard SEAS have developed an injectable, biomaterial-based vaccine that, when combined with standard chemotherapy, caused complete and lasting recovery from and immunity against AML in mice. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 14, 2020 Category: Cancer & Oncology Source Type: news

Vitamin B6, leukemia's deadly addiction
Scientists have discovered that Acute Myeloid Leukemia (AML) grows by taking advantage of the B6 vitamin to accelerate cell division. The research team from Cold Spring Harbor Laboratory (CSHL) and Memorial Sloan Kettering Cancer Center (MSK) suggest they could halt the growth of this cancer by limiting its ability to manipulate the enzyme that pushes B6 to make proteins essential for cell division. (Source: World Pharma News)
Source: World Pharma News - January 13, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Vitamin B6, leukemia's deadly addiction
(Cold Spring Harbor Laboratory) Researchers from CSHL and Memorial Sloan Kettering Cancer Center have discovered how Acute Myeloid Leukemia is addicted to vitamin B6. Now that researchers know this, they can pursue new treatment options for the deadly blood cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 13, 2020 Category: Cancer & Oncology Source Type: news

Naval Daver, MD, Provides Perspective on Updates in Acute Myeloid Leukemia
Naval Daver, MD, explains the progress made on 3 abstracts he ’s involved with regarding acute myeloid leukemia (AML) at the ASH Annual Meeting and Exposition. (Source: CancerNetwork)
Source: CancerNetwork - January 12, 2020 Category: Cancer & Oncology Authors: Naval Daver, MD Source Type: news

Courtney DiNardo, MD, MSCE, on Enasidenib Plus Azacitidine in Newly Diagnosed AML
Courtney DiNardo, MD, MSCE, elaborated on interim phase II results regarding enasibenib plus azacitidine in patients with newly diagnosed acute myeloid leukemia, and the results from the QUAZAR trial. (Source: CancerNetwork)
Source: CancerNetwork - January 10, 2020 Category: Cancer & Oncology Authors: Courtney DiNardo, MD, MSCE Source Type: news

Intrexon will take the name of its subsidiary. That company just scored orphan status for a rare cancer drug.
Just four days after Intrexon Corp. (NASDAQ: XON) made public plans to rebrand as Precigen, its subsidiary by the same name has secured a coveted regulatory designation for its blood cancer treatment. Germantown’s Precigen Inc. has earned orphan drug status from the Food and Drug Administration for its therapy for relapsed or refractory acute myeloid leukemia, a form of cancer in the blood and bone marrow, in cases that have either come back or failed to respond to past treatment. The company … (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 6, 2020 Category: Pharmaceuticals Authors: Sara Gilgore Source Type: news

Intrexon will take the name of its subsidiary. That company just scored orphan status for a rare cancer drug.
Just four days after Intrexon Corp. (NASDAQ: XON) made public plans to rebrand as Precigen, its subsidiary by the same name has secured a coveted regulatory designation for its blood cancer treatment. Germantown’s Precigen Inc. has earned orphan drug status from the Food and Drug Administration for its therapy for relapsed or refractory acute myeloid leukemia, a form of cancer in the blood and bone marrow, in cases that have either come back or failed to respond to past treatment. The company … (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 6, 2020 Category: Biotechnology Authors: Sara Gilgore Source Type: news

Brentuximab Vedotin with Re-induction Chemotherapy Effective, Well Tolerated in AML
A phase I study showed brentuximab vedotin combined with a standard chemotherapy regimen of mitoxantrone, etoposide, and cytarabine may be safe and well tolerated in patients with relapsed/refractory acute myeloid leukemia. (Source: CancerNetwork)
Source: CancerNetwork - January 3, 2020 Category: Cancer & Oncology Authors: Kevin Wright Source Type: news

Closer to identifying leukemic stem cells
(Josep Carreras Leukaemia Research Institute) Researchers at the Josep Carreras Leukaemia Research Institute have developed innovative diagnostic trials to identify cells resistant to leukemia treatment. These new trials allow the identification of a subgroup of patients with an unfavorable prognosis at the time of diagnosis of acute myeloid leukemia. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 2, 2020 Category: International Medicine & Public Health Source Type: news

AML Highlights From the 2019 ASH Annual Meeting AML Highlights From the 2019 ASH Annual Meeting
Dr Harry Erba reviews several studies presented at the ASH 2019 annual meeting that have practice-changing implications for treating acute myeloid leukemia.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 30, 2019 Category: Consumer Health News Tags: None ReCAP Source Type: news

Artificial intelligence tracks down leukemia
(DZNE - German Center for Neurodegenerative Diseases) Artificial intelligence can detect one of the most common forms of blood cancer - acute myeloid leukemia -- with high reliability. Researchers at the DZNE and the University of Bonn have now shown this in a proof-of-concept study. Their approach is based on the analysis of the gene activity of cells found in the blood. Used in practice, this approach could support conventional diagnostics and possibly accelerate the beginning of therapy. The research results have been published in the journal 'iScience'. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 20, 2019 Category: Cancer & Oncology Source Type: news

Medical doctors STUNNED as bone marrow transplant for leukemia treatment changes man’s DNA, proving medical interventions can OVERWRITE your genetic code
(Natural News) A Nevada man was shocked to learn that a bone marrow transplant he received actually changed his DNA and replaced it with that of his German donor. Chris Long of Reno is currently in remission from acute myeloid leukemia. Three months after his bone marrow transplant operation, he discovered that the DNA in... (Source: NaturalNews.com)
Source: NaturalNews.com - December 19, 2019 Category: Consumer Health News Source Type: news

Acute leukemia patients treated with common therapy have increased risk for heart failure
(University of Pennsylvania School of Medicine) Patients with acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) who are treated with anthracyclines are at a heightened risk of heart failure -- most often within one year of exposure to the chemotherapy treatment, according to a new study led by researchers at Penn Medicine. To help identify a patient's risk for heart failure following the treatment, researchers developed a risk score (0 to 21) based on clinical and echographic variables. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 17, 2019 Category: Cancer & Oncology Source Type: news

Oral Azacitidine: First Maintenance Therapy for AML Oral Azacitidine: First Maintenance Therapy for AML
A new oral formulation of azacitidine (CC-486) significantly improved overall survival when used as maintenance therapy in patients with acute myeloid leukemia (AML).Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 10, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Research revises classification of acute myeloid leukemia & myelodysplastic syndrome
(St. Jude Children's Research Hospital) Findings presented as a late-breaking abstract at the American Society of Hematology annual meeting by St. Jude Children's Research Hospital showcase the power and potential of combining genomic and transcriptomic data. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 10, 2019 Category: Cancer & Oncology Source Type: news

No Decreased Survival in Blacks With AML Compared With Whites No Decreased Survival in Blacks With AML Compared With Whites
Although blacks with acute myeloid leukemia were more likely to have evidence of abnormal kidney function, the excess of this comorbidity didn't affect overall survival, compared with whites.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 8, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Comparative Analysis of Patterns of Infectious Complications of Outpatient Vs. Inpatient Care Following Intensive Induction Chemotherapy for Adults with Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasms
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - December 6, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

Acute Myeloid Leukemia and Antifungal Prophylaxis Era: Compliance of AML Centers, Invasive Fungal Infection (IFI) Classification, IFI Incidence and AML Outcomes from ALFA 2007- 02 Study
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - December 6, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

Survival Benefits from Antifungal Prophylaxis and a Dedicated Inpatient Malignant Hematology Service during Induction Chemotherapy for Acute Myeloid Leukemia
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - December 5, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

Phase I/II Studies of Annamycin in Acute Myeloid Leukemia Report Positive Interim Results
Additional positive interim safety and efficacy data were reported for annamycin in the treatment of patients with relapsed or refractory acute myeloid leukemia. (Source: CancerNetwork)
Source: CancerNetwork - December 4, 2019 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Impact of Invasive Aspergillosis occuring during remission-induction therapy on outcome of Acute Myeloid Leukemia (SEIFEM 2012B Study).
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - November 12, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

Retrospective analysis of invasive aspergillosis in pediatric patients with acute myeloid leukemia
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - November 12, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

Isavuconazole (ISAV) as Primary Anti-Fungal Prophylaxis (PAP) in Patients (pts) with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS): An Open-Label, Prospective Study
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - November 12, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

AI-driven single blood cell classification
(Helmholtz Zentrum M ü nchen - German Research Center for Environmental Health) For the first time, researchers from Helmholtz Zentrum M ü nchen and the University Hospital of LMU Munich show that deep learning algorithms perform similar to human experts when classifying blood samples from patients suffering from acute myeloid leukemia (AML). Their proof of concept study paves the way for an automated, standardized and on-hand sample analysis in the near future. The paper was published in Nature Machine Intelligence. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 12, 2019 Category: Cancer & Oncology Source Type: news

Gilteritinib Improves Survival in Patients with Relapsed/Refractory FLT3+ AML
Treatment with gilteritinib improved survival and increased remission rates, compared with salvage chemotherapy, among patients with relapsed or refractory FLT3-mutated acute myeloid leukemia. (Source: CancerNetwork)
Source: CancerNetwork - November 1, 2019 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

Gilteritinib Superior in Relapsed, Refractory FLT3-Mutated AML
THURSDAY, Oct. 31, 2019 -- For relapsed or refractory acute myeloid leukemia (AML) with mutations in the FMS-like tyrosine kinase 3 gene (FLT3), treatment with a selective FLT3 inhibitor, gilteritinib, results in significantly longer survival and a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 31, 2019 Category: Pharmaceuticals Source Type: news

SY-1425 Combination Shows Promise in Acute Myeloid Leukemia Subgroup
Treatment with SY-1425 in combination with azacitidine induced a 62% complete response rate with incomplete blood count recovery rate among unfit patients with RARA-positive AML. (Source: CancerNetwork)
Source: CancerNetwork - October 31, 2019 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

European Commission Approves Astellas' XOSPATA(TM) for Patients with Relapsed or Refractory Acute Myeloid Leukemia with Mutations Detected using Invivoscribe's LeukoStrat(R) CDx FLT3 Mutation Assay
SAN DIEGO, Oct. 30, 2019 -- (Healthcare Sales & Marketing Network) -- Invivoscribe, Inc. announced today that the European Commission (EC) has approved the Astellas drug XOSPATA™ (gilteritinib) as a monotherapy for the treatment of adult patients with rel... Diagnostics, Oncology, Regulatory Invivoscribe, Astellas, XOSPATA, gilteritinib, LeukoStrat CDx FLT3 (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 30, 2019 Category: Pharmaceuticals Source Type: news

European Commission Approves Astellas' XOSPATA(TM) (gilteritinib) as a Monotherapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation
Approval follows accelerated assessment, orphan designation by European Medicines Agency TOKYO, Oct. 25, 2019 -- (Healthcare Sales & Marketing Network) -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") ... Biopharmaceuticals, Oncology, Regulatory Astellas Pharma, XOSPATA, gilteritinib, acute myeloid leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 25, 2019 Category: Pharmaceuticals Source Type: news

Outcomes Associated with Antimicrobial Use during High Dose Cytarabine Consolidation in Acute Myeloid Leukemia
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 10, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

Isavuconazole (ISAV) As Primary Anti-Fungal Prophylaxis in Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective Study
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 8, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

Seifem 2016 Study: Incidence of Probable and Proven Invasive Aspergillosis in Patients with Acute Myeloid Leukemia during Consolidation Therapy
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 6, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

Invasive Aspergillosis (IA) in Acute Myeloid Leukemia (AML): When Is Prophylaxis Appropriate?
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 6, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

Therapeutic Drug Monitoring of Posaconazole in Adult Acute Myeloid Leukemia (Aml) Patients Receiving Posaconazole Prophylaxis during Induction: Experience from a Center with High Invasive Fungal Infection (IFI)Burden
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 4, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

Novel Risk Factors for Predicting the Development of Invasive Fungal Infections in Acute Myeloid Leukemia Patients Undergoing Induction and Re-Induction Chemotherapy
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 4, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

Comparison of Micafungin and Liposomal Amphotericin B for Empirical Antifungal Therapy in Febrile Neutropenic Patients with Acute Myeloid Leukemia: A Randomized Controlled Trial
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 4, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

Prophylactic Use of Voriconazole for Invasive Fungal Infection in Children and Adolescents with Acute Myeloid Leukemia
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - September 20, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

Survey of Serum Aspergillus Antigen in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia or Allogeneic Hematopoietic Stem Cell Transplantation: Role in Predicting Invasive Aspergillosis and in Modifying the Therapeutic Strategy
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - September 20, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

New Option Soon for Some European Patients With Leukemia New Option Soon for Some European Patients With Leukemia
Gilteritinib has been recommended for approval for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) with an FLT3 mutation.International Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 20, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Practical Dosing Considerations for Venetoclax
With FDA-approved indications for both chronic lymphocytic leukemia and acute myeloid leukemia, and continued investigation within multiple disease states, venetoclax has become an exciting oral targeted therapy among oncologists.   (Source: CancerNetwork)
Source: CancerNetwork - September 20, 2019 Category: Cancer & Oncology Authors: Kelly Valla, PharmD, BCOP Source Type: news

BioTheryX, Inc. Announces the Appointment of Biopharma Veteran Jeffrey L. Edwards to Board of Directors
BioTheryX plans to continue building out Board of Directors with key biopharma industry leaders as Company transitions from preclinical to clinical stage with lead Acute Myeloid Leukemia ("AML") compound BTX-A51 CHAPPAQUA, N.Y., Sept. 18, 2019... Biopharmaceuticals, Oncology, Personnel BioTheryX, Protein Homeostatic Modulators (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 18, 2019 Category: Pharmaceuticals Source Type: news

Many Older Patients With AML Not Receiving Active Treatment
WEDNESDAY, Sept. 18, 2019 -- Many older patients with acute myeloid leukemia (AML) do not receive any active treatment, and they have worse survival than those receiving active treatment, according to a study published online Sept. 4 in Cancer. Amer... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 18, 2019 Category: Pharmaceuticals Source Type: news

Gilteritinib Changes AML Landscape
The US Food and Drug Administration recently approved gilteritinib (Xospata), in addition to final trial data from the phase 3 ADMIRAL trial, making it the new standard of care for acute myeloid leukemia. (Source: CancerNetwork)
Source: CancerNetwork - August 23, 2019 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news

Washington University gets $15M grant to study leukemia
Washington University investigators at Siteman Cancer Center at Barnes-Jewish Hospital and the School of Medicine have been awarded a $15 million grant to study the genetic changes that drive acute myeloid leukemia (AML), a deadly blood cancer. Findings from their studies may help develop more effective therapies for patients, officials said. The grant is funded by the National Cancer Institute of the National Institutes of Health. Earlier funding for AML and a gift from Alvin Siteman allowed… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 22, 2019 Category: Biotechnology Authors: Veneta Rizvic Source Type: news